日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy

二十年来,Fabry 结局调查的经验进一步证实了阿加糖酶α酶替代疗法的长期疗效。

Ramaswami, Uma; Pintos-Morell, Guillem; Kampmann, Christoph; Nicholls, Kathleen; Niu, Dau-Ming; Reisin, Ricardo; West, Michael L; Anagnostopoulou, Christina; Botha, Jaco; Jazukeviciene, Dalia; Schenk, Jörn; Hughes, Derralynn A; Giugliani, Roberto

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis

法布里病预后调查分析显示,及时启动阿加糖酶α治疗与肾脏和心血管预后改善相关。

Hughes, Derralynn; Linhart, Aleš; Gurevich, Andrey; Kalampoki, Vasiliki; Jazukeviciene, Dalia; Feriozzi, Sandro